No dip for these chips.
Intel clocks a one-year high.
Stock still a good value. [more]
Flavors, spice and rice.
McCormick bakes up a high.
Dough for shareholders.
A couple of weeks back, I blogged about an arbitrage opportunity with Gilead's offer to buy Pharmasset (VRUS). Many of these deals don't offer a big enough spread to risk CAPS points since the SPY etf might move by more than enough to cover the spread. [more]
As some may know, I've been negative (and wrong) about long-term Treasuries for some time. After 10-year T-notes ended '11 as one of the best performering investments, I decided to run some numbers for a Fool article (not a video). [more]